Nektar To Announce Financial Results For The Second Quarter Of 2017 On Tuesday, August 8, 2017, After Close Of U.S.-Based Financial Markets

SAN FRANCISCO, Aug. 2, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2017, on Tuesday, August 8, 2017, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, September 11, 2017.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 62434800  (Nektar Therapeutics is the host)

About Nektar Therapeutics

Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact: 
For Investors and Media: 
Jennifer Ruddock of Nektar Therapeutics
415-482-5585

View original content:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-second-quarter-of-2017-on-tuesday-august-8-2017-after-close-of-us-based-financial-markets-300498783.html

SOURCE Nektar Therapeutics